Signing Ceremony of The Collaboration in Manufacturing Rabies Vaccine between Queen Saovabha Memorial Institute, The Thai Red Cross Society, BioNet-Asia Co., Ltd. And Liaoning Cheng Da Biotechnology Co., Ltd. The People’s Republic of China on 16 September 2014, Sabhanayika Building, Queen Saovabha Memorial Institute,The Thai Red Cross Society, Bangkok.
BANGKOK, Sept 16 (PNA/Bernama) — The Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society, BioNet-Asia and Liaoning Cheng Da Bioechnology (CDBIO) have announced a collaboration to manufacture the next-generation rabies vaccine in Thailand.
The project is now in its ultimate phase of manufacturing at QSMI’s facilities after a few years of joint development by the three parties.
“Through this partnership, QSMI will be able to manufacture rabies vaccine in its production plant and supply it along with the currently produced immunoglobulin,” said QSMI director Prof Dr Visith Sitprija at the signing of the manufacturing collaboration agreement today.
QSMI is a World Health Organization Collaborating Centre for Research on Rabies Pathogenesis and Prevention.
BioNet-Asia managing director Vitoon Vonghangool said the clinical results of CDBIO’s highly purified rabies vaccine have led to this joint initiative of locally developing and manufacturing the new rabies vaccine using the same innovative technology.
BioNet-Asia is an independent vaccine company.
Meanwhile, CDBIO director Li Ning said CDBIO’s vaccines against rabies and Japanese encephalitis using cell-culture technology have been widely used in Asia.
He said the company has supplied more than 180 million doses of its rabies vaccine Speeda, which is exported to more than 20 countries, and in Thailand in the first half of this year more than a million doses of Speeda have been sold.
He said since its launch into the market in 2005, Speeda has broken transnational corporations’ monopoly of high-end rabies vaccine for human use in China, where it now leads the market.